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Abstract
One eye of rd12 mice received a sub-retinal injection of a vector carrying normal human RPE65 cDNA at post-natal day 18, and at
6- and 13-months of age. Electroretinograms (ERGs) and visual-evoked potentials (VEPs) were recorded to luminance, and to spatially
and temporally modulated stimuli to assess the consequences of delayed treatment on visual pathway function. Early treatment resulted
in better overall retinal rescue and better rescue of cone-mediated function. VEPs to low temporal frequency luminance modulation were
well preserved at all but the oldest treatment age and corresponded to predictions based on the amount of retinal rescue. In contrast,
VEPs to high frequency spatially and temporally modulated stimuli were impaired even at the earliest age. These results provide further
support that early treatment in human LCA will have the most hope for optimal visual performance.
© 2006 Elsevier Ltd. All rights reserved. 
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Mutations in the RPE65 gene cause the early onset reti-
nal disease Leber Congenital Amaurosis (LCA). The
RPE65 protein is the isomerase responsible for the conver-
sion of all-trans retinaldehyde (all-trans retinal) to photoac-
tive 11-cis retinaldehyde (11-cis retinal) and is essential for
normal function of the visual cycle (Jin, Li, Moghrabi, Sun,
& Travis, 2005). Disruption of the RPE65 gene results in
the accumulation of all-trans-retinyl esters and the reduc-
tion of rhodopsin in the rod photoreceptor outer-segment.
In humans and animals, the absence of rhodopsin leads to
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doi:10.1016/j.visres.2006.05.010severe retinal abnormalities (Redmond et al., 1998; Thomp-
son et al., 2000). Clinically, LCA is characterized as an early
onset and severe form of inherited retinal dystrophy with
features of retinal pigmentary degeneration, night blindness
and severely compromised or absent rod and cone electro-
retinographic (ERG) signals (Thompson et al., 2000).
Attempts to rescue the normal phenotype in animal
models of LCA using gene replacement therapy and phar-
maceutical strategies have proven successful (Acland et al.,
2005; Dejneka et al., 2004; Lai et al., 2004; Pang et al., 2006;
Van Hooser et al., 2000). A naturally occurring canine
model, the Swedish Briard beagle, shows almost total visual
impairment at birth as a result of a homozygous 4 base-pair
deletion in exon 5 of the canine RPE65 gene (Veske, Nils-
son, Narfstrom, & Gal, 1999). Gene therapy using a rAAV
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retinal function in this animal model (Acland et al., 2001).
Gene replacement therapy in a targeted knockout mouse
(Rpe65¡/¡tm1Tmr) model of LCA has also been successful
(Lai et al., 2004). More recently, rAAV-mediated RPE65
gene delivery to a naturally occurring mouse model of
human LCA, the rd12 mouse (Pang et al., 2005a), also suc-
cessfully restored retinal biochemistry and function (Pang
et al., 2006).
Gene replacement therapy performed early in the course
of the disease seems to hold the most promise of success.
Delivery of the human RPE65 cDNA to retinal pigment
epithelium cells of Rpe65¡/¡tm1Tmr homozygous mouse
fetuses resulted in ERG b-wave thresholds that were near
normal, and amplitudes that were sizeable, although abnor-
mal, and when delivered at 1–2.5 months post-natal, was
about 80% successful by ERG when assayed two months
later (Dejneka et al., 2004). rd12 mice injected at post-natal
day 14 (P14) with a rAAV5-CBA-hRPE65 vector resulted
in RPE65 expression over large areas of RPE, improved
rhodopsin levels, and ERG signals that were approximately
66% of normal when assayed at 7-months of age
(Pang et al., 2006). However, gene therapy at advanced-dis-
ease stages appears to be far less successful. When treated
at 17–24 months of age, gene replacement therapy in
Rpe65¡/¡tm1Tmr homozygous mice resulted in a statistical
improvement in ERG responses in only 4 of 25 mice (16%)
and retinal biochemistry was restored in only 5 of 17 mice
(29%) (Jacobson et al., 2005). In addition, when treated at
early ages, the extent of retinal biochemical and functional
rescue appears to be sustainable for at least seven months
in the rd12 mouse model of LCA (Pang et al., 2005a) and
up to Wve years in the Briard dog (Acland et al., 2005; Narf-
strom et al., 2003b).
Collectively, the studies cited above support early inter-
vention as having the most hope for signiWcant retinal res-
cue, both in terms of the number of eyes rescued and the
amount of retina that is restored. However, the full phe-
nomenon of vision is deWned not only by an intact retinal
response but also by the integrity of cells and neural con-
nections throughout the visual pathway from the retina to
the primary visual cortex. The interaction of neural cells
and information processing throughout the visual system
deWne complex visual abilities, such as spatial and temporal
resolution, and luminance and color discrimination. These
visual abilities are reWned during development and depend
on neural activity initiated at the level of the retina. In
humans and animals, severe functional deWcits are known
to occur as a result of depriving or limiting sensory input to
these visual channels (see, for example, (JeVrey, Birch,
Stager, Stager, & Weakley, 2001; Lewis, Maurer, & Brent,
1986; Lickey, Pham, & Gordon, 2004; Prusky, West, &
Douglas, 2000)).
One method of evaluating the functional integrity of
the visual pathway is to record visual-evoked potentials
(VEPs). In the studies reported here, we examined several
aspects of cortical visual function using the VEP in therd12 mouse model of LCA after gene replacement ther-
apy to restore retinal function. Gene therapy was per-
formed at post-natal day 18 (P18), at 6-months, and at
13-months of age, and our main goal was to determine
the consequences of delayed treatment on cortical visual
function.
2. Materials and methods
2.1. Mice
The rd12 mutant mouse, originally discovered at the Jackson Labora-
tory, was used in these studies (Pang et al., 2005a). The rd12 mutation is
caused by a nonsense mutation in exon 3 of the Rpe65 gene. Functional
and biochemical studies conWrm that vitamin A metabolism and visual
processing are disrupted in the rd12 mouse. Retinal function measured
with the ERG is non-detectable at the earliest ages (1-month) except at the
brightest stimulus intensities, while retinal morphology remains relatively
intact for up to 7–8 months, although retinal “voids” begin to appear in
the photoreceptor architecture as early as 6-weeks of age (Pang et al.,
2005a). Normal age-matched C57BL/6J mice were used as controls. All
mice were maintained in the University of California Animal Facilities
under a 12/12-h light/dark cycle. All experiments were approved by the
University of California Institutional Review Board and conducted in
accordance with the ARVO Statement for the Use of Animals in Ophthal-
mic and Vision Research.
2.2. Gene therapy
The rd12 mice were treated with a serotype 5 recombinant adeno-
associated virus (rAAV5) vector carrying a normal human RPE65
cDNA injected sub-retinally at post-natal day 18 (P18) (N D 4), at
6-months (N D 4), and at 13-months of age (N D 1). Methods for gener-
ating treatment vectors have been described previously (Pang et al.,
2006).
2.3. Rhodopsin measurements
To determine if rhodopsin is regenerated in treated rd12 eyes, we puri-
Wed pigment from eyecup lysates from the treated and untreated eyes of
rd12 mice and from age-matched C57BL/6J control mice by immunoaYn-
ity chromatography as previously described (Pang et al., 2006).
2.4. Visual function tests
All visual function tests were performed two months after gene
replacement therapy. The ERG and VEP were used to evaluate the
status of retinal and cortical visual function, respectively. A normal
VEP requires an intact visual pathway from the retina to the primary
visual cortex and the relationship between ERG and VEP signals is a
powerful tool to evaluate the functional integrity of cells throughout
the visual pathway (Ridder, III & Nusinowitz, 2006). Except for the
placement of the recording electrode (cornea for the ERG; visual cor-
tex for the VEP), stimuli were identical for both procedures. Intensity-
response functions were determined for rod-mediated vision, temporal
tuning functions were derived under both dark- and light-adapted con-
ditions to estimate critical Xicker fusion frequencies (CFFs), and cone-
mediated responses to spatially modulated stimuli were measured with
the sweep VEP to determine visual acuity. Methods for recording
ERGs and VEPs in the mouse, and for estimating response parameters,
have been described (Ridder, III & Nusinowitz, 2006). Each mouse was
examined with a slit lamp before and after testing to ensure the absence
of media opacities. In addition, a custom made rigid gas-permeable
contact lens was placed on the corneal surface during testing with pat-
tern stimuli to eliminate transient cataract formation (Ridder, III &
Nusinowitz, 2002, 2006).
3928 S. Nusinowitz et al. / Vision Research 46 (2006) 3926–39343. Results
3.1. Rhodopsin measurements
The UV–visible spectra of the eluted samples are shown
in Fig. 1 for representative mice treated at P18, and at 6-
and 13-months. The normal max of rhodopsin visual pig-
ment (500 nm) was seen in the treated rd12 eyes at each age
of treatment, whereas the untreated eye showed no absorp-
tion in the 500-nm region. The UV spectra also detected the
puriWed opsin protein peak at a max of 280 nm in treated
eyes. Compared to wild-type controls, the absorption spec-
trum from the treated rd12 eyes indicated that rhodopsin
was restored to about 50% of the normal level for the P18
group, 30% for the mice treated at 6-months, and 23% for
the single mouse treated at 13-months.3.2. Rod ERG and VEP intensity-response functions
3.2.1. ERGs
ERG intensity-response (I-R) functions obtained under
dark-adapted conditions are shown in Fig. 2A for the
normal controls (n D 4) and for the rd12 eyes treated at P18
(n D 4), and at 6- (n D 4) and 13- (n D 1) months of age. Each
response function was Wtted with a Naka–Rushton equa-
tion to estimate Vmax, the saturated amplitude, and k, the
semi-saturation intensity. The response functions for each
of the three groups of treated rd12 eyes are displaced down-
ward from normal controls (Wlled circles) consistent with
partial restoration of retinal function in these eyes.
Untreated control eyes (open diamonds) show detectable,
although severely abnormal, responses at only the highest
stimulus intensities.Fig. 1. Representative UV–visible spectrum of immunoaYnity-puriWed rhodopsin samples from the three ages of treatment. AYnity-bound rhodopsin has
a max of approximately 500 nm in samples from normal C57BL/6 (controls; heavy lines) and AAV5-CBA-hRPE65-treated rd12 retina (thin lines), but is
undetectable from untreated rd12 retinas (dashed lines).Fig. 2. Dark-adapted intensity-response functions for ERGs (A) and VEPs (B). Open circles, squares, and triangles show the data from rd12 mice treated
at P18, 6-months, and 13-months, respectively, compared to normal controls (Wlled circles). Measurements were made 2-months post-treatment. Error
bars are §1 Standard Error (SE). In 2B, dashed lines are the predicted VEP intensity-response functions for the three groups of mice estimated from the
extent of retinal rescue (see text for details).
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trols and for the three rd12 treatment groups, are 302.8
(§26.8), 145.4 (§14.3), 116.0 (§8.44), and 91.3V, respec-
tively. Compared to the normal data, the change in Vmax sug-
gests a functional recovery of about 48% for the rd12 mice
treated at P18, 38% for the mice treated at 6-months, and 30%
for the single mouse treated at 13-months. The estimate for k,
the semi-saturation intensity, was 0.015 (§0.0056), 0.0211
(§0.006), 0.067 (§0.026), and 0.044 scotopic td-s, for normal
mice, and mice treated at P18, and at 6- and 13-months,
respectively. (The mouse treated at 3-months is not represen-
tative of the level of treatment success at this age and was one
of a few that showed signiWcant retinal rescue. This mouse
was included in this study to examine the eVects on cortical
function after a relatively long period of limited retinal input,
which was the primary goal of this study.)
3.2.2. VEPs
VEP intensity-response (I-R) functions are shown in
Fig. 2B. Vmax and k were estimated for each response func-
tion as described above. The Vmax amplitude (§SE) for the
normal controls and the rd12 mice treated at P18, and at 6-
and 13-months, are 56.3 (§10.8), 29.5 (§6.5), 19.7 (§3.43),
and 12.4V, respectively. Compared to the normal VEP
data, the saturated amplitude (Vmax) suggests a level of cor-
tical function of about 52% at P18, 35% at 6-months, and
22% at 13-months. The estimates for k for the four groups
of mice, are 0.0075 (§.002), 0.0147 (§0.009), 0.182 (§0.166),
and 0.29 scotopic td-s, respectively. The shift in k between
the P18 and 6-months treatment groups was not statisti-
cally diVerent for ERG measurements (t D 1.626, p D 0.082)
or for the VEP measurements (t D 1.47, p D 0.10), although
there was a trend in the direction of reduced sensitivity
(higher values of k) in the VEP measurements over this age
range. The change in k in the VEP measurements for the
mouse treated at 13-months was much greater than that
observed for the ERG measurements when compared to
the earlier treatment ages, suggesting a loss of function of
the visual pathway for this mouse.Shown in Fig. 2B as dashed lines are the predicted VEP
response functions that were derived, as a Wrst approxima-
tion, by scaling the normal VEP intensity-response function
by the amount of retinal rescue for each group. The actual
data agree well with the predicted response functions at P18
and at 6-months. The data for the 13-month treatment
mouse are more variable and tend to fall below the pre-
dicted response function at most stimulus intensities. Nev-
ertheless, the correspondence between the actual and
predicted response functions suggests relative preservation
of visual pathway function for all but the oldest treatment
age in the processing of low temporal frequency luminance
modulations.
3.3. ERG and VEP temporal-response functions
3.3.1. ERGs
Dark-adapted ERG temporal-response functions are
shown in Fig. 3A. The response function for normal mice
(Wlled circles) is consistent with a low-pass Wlter as previ-
ously described (Ridder, III & Nusinowitz, 2006). The
response functions for the treated rd12 eyes (open symbols)
are also low pass although they are displaced downward in
the graph to lower response amplitudes at most temporal
frequencies.
Shown in Fig. 3A, as dashed lines, are the predicted
dark-adapted ERG temporal-response functions if ampli-
tudes are scaled by the amount of retinal rescue at all tem-
poral frequencies. Vmax, derived from the intensity-response
functions described above, was used to scale the temporal-
response functions. The response function for the rd12 eyes
treated at P18 fall close to predicted function at temporal
frequencies below 10 Hz. Above 10 Hz, response amplitudes
fall within the normal range (Wlled circles). The data for the
6-month treatment group demonstrate the same pattern,
including the inXection at 10 Hz, where responses are some-
what better than predicted. Response amplitudes for the
13-month treatment group fall below predicted values at all
temporal frequencies, and the inXection to better thanFig. 3. Dark- (A) and light- (B) adapted ERG temporal-response functions. Filled circles are normal age-matched controls. Other data symbols are as in
Fig. 1. Dashed lines in (A) are predictions estimated from the extent of retinal rescue as indexed by Vmax, the maximum saturated amplitude (see text for
details).
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the biphasic response proWle at P18 and 6-months will be
deferred until the Section 4.
Each temporal-response function was Wt with a double-
exponential function with four Xoating variables (peak
response amplitude, peak temporal frequency, high tempo-
ral frequency slope, and low temporal frequency slope) to
determine the CFF (Ridder, III & Nusinowitz, 2006). The
CFF was extrapolated by extending the curve to the
average noise level for the ERG for each of the three
treatment groups. The average noise level was determined
by recording the response to a ‘blank’ trial in the absence of
a visual stimulus. The average noise level for the three treat-
ment groups was 1.6, 1.4, and 1.5V, respectively. Because
of the pronounced biphasic response function for the P18
group, only the data above 8 Hz was included in the Wt for
this group. Based on this Wt, the dark-adapted CFF for the
rd12 mice treated at P18, and 6- and 12-months of age are,
31.6, 18.6, and 20.0 Hz, respectively. The dark-adapted CFF
for normal control mice is 26.2 Hz. (r2 describing the Wt of
the equation to the data was 0.96, 0.97, and 0.99 for the
three groups of treated rd12 mice, respectively.)
Light-adapted ERG temporal-response functions are
shown in Fig. 3B. In normal mice, the light-adapted ERG
temporal-response function is consistent with a band-pass
Wlter with a peak amplitude at approximately 3 Hz. The
response functions for all treated rd12 eyes also demon-
strate band-pass Wltering. The response function for eyes
treated at P18 are indistinguishable from normal up to
approximately 7 Hz, and then depart from the normal
curve for higher temporal frequencies. The temporal-
response functions for the mice treated at 6- and 13-months
of age are below normal limits at all temporal frequencies.
The CFFs for the rd12 mice treated at P18, 6- months, and
13-months are 38.7, 16.5, and 26.5 Hz, respectively. The
light-adapted CFF for normal control mice is 41.3 Hz. (The
average noise level for the three groups is 1.4, 1.9, and
1.4V, respectively, with r2 values describing the Wt of the
equation to the data was 0.96, 0.92, and 0.80, respectively.)3.3.2. VEPs
Dark-adapted VEPs (Fig. 4A) in normal mice demon-
strate band-pass Wltering with a peak response at approxi-
mately 2 Hz with a slow roll-oV of response amplitudes on
either side of the peak frequency. In contrast, the response
functions for the treated rd12 eyes have shifted from band-
pass to low-pass Wltering for all treatment groups.
In Fig. 4A, the dashed lines are the normal VEP tempo-
ral-response functions scaled by the amount of retinal
rescue for each of the three treatment groups as described
above. Departures from these predicted responses would be
consistent with disruptions of visual pathway processing of
temporal information. The data collected for all the treated
rd12 eyes fall below expected values at all temporal fre-
quencies except 1.0 Hz. In addition, there is a systematic
loss of high temporal-response sensitivity with age of treat-
ment. These observations would suggest a loss of high tem-
poral frequency resolution in the post-retinal visual
pathway since this same pattern of high frequency loss
was not observed in the ERG responses over the same
range of temporal frequencies (see Fig. 3A). The dark-
adapted VEP CFFs for the rd12 mice treated at P18,
6-months, and 13-months are 5.3, 6.6, and 3.9 Hz, respec-
tively compared to 7.1 Hz for normal control mice. (The
average dark-adapted VEP noise level for the three groups
is 3.4, 1.6, and 1.6V, respectively, with r2 values of 0.99,
0.94, and 0.99, respectively).
Light-adapted VEP temporal-response functions (Fig. 4B)
are displaced downward in the graph to lower overall
response amplitudes, well outside the normal range, and
there is a systematic loss of high temporal frequency res-
olution with age of treatment just as for the dark-
adapted responses. The light-adapted VEP CFFs for the
rd12 mice treated at P18, 6-months, and 13-months are
6.8, 5.9, and 2.4 Hz, respectively. The light-adapted CFF
for normal controls is 9.0 Hz. (The average light-adapted
VEP noise level for the three groups is 1.5, 3.1, and
3.1 V, respectively, with r2 values of 0.91, 0.97, and 0.97,
respectively.)Fig. 4. Dark- (A) and light- (B) adapted VEP temporal-response functions. Data symbols are as in Fig. 3. Dashed lines in (A) are predictions estimated
from the extent of retinal rescue as indexed by Vmax, the maximum saturated amplitude (see text for details).
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Visual acuities were determined with the sweep VEP
(Ridder, III & Nusinowitz, 2006). BrieXy, the sweep VEP
stimulus consisted of a horizontally oriented sine wave grat-
ing of eleven spatial frequencies (0.10, 0.12, 0.16, 0.20, 0.25,
0.32, 0.40, 0.50, 0.63, 0.80, and 0.98 cpd) presented at a tem-
poral reversal rate of 4 Hz. Each spatial frequency was pre-
sented for 1 s so that the entire sweep took 12 s (11 spatial
frequencies + 1 s pre-adaptation). Forty to Wfty sweeps were
recorded for each mouse. Two methods, that depended on
the number of data points above noise, were employed to
extrapolate the acuity of each mouse (Ridder, III et al.,
1998). The Wrst method utilized a linear Wt to the sweep VEP
data. Acuities were determined by Wtting a line between the
high spatial frequency data that were above noise and the
Wrst spatial frequency that entered noise. The data were
determined to be noise if the 95% conWdence intervals for
the sweep VEP amplitude data overlapped with zero. The
second method of acuity determination was employed if
there were no data points between the peak spatial fre-
quency and the noise level. Under these circumstances, the
acuity was taken as the highest spatial frequency response
that was above noise. Using these methods, the average
visual acuity for the normal controls (n D8), and the rd12
mice treated at P18, 6-months, and 13-months of age, are
0.69 (§0.08), 0.403 (§0.14), 0.605 (§0.13), and 0.10 cycles/
degree, respectively. Equivalent average Snellen visual acu-
ities are 20/870, 20/1489, 20/976, and 20/6000 for the four
groups of mice. The estimate of visual acuity for normal
controls is consistent with that previously reported using the
same methodology (Ridder, III & Nusinowitz, 2006).
Results for individual mice are given in Table 1.
4. Discussion
4.1. Retinal function after gene replacement therapy in the 
rd12 mouse model of LCA
As previously described, signiWcant functional rescue
was observed in rd12 retinas treated with a sub-retinal
Table 1
Treatment age Mouse # Visual acuity (cpd) Snellen equivalent
P18 M1 0.29 20/2069
M2 0.40 20/1500
M3 0.32 20/1875
M4 0.60 20/1000
Mean (§SD) 0.403 (§0.14) 20/1489
6-months M1 0.80 20/750
M2 0.50 20/1200
M3 0.56 20/1071
M4 0.60 20/1000
Mean (§SD) 0.615 (§0.13) 20/976
13-months M1 0.10 20/6000
Normal N D 8 0.69 (§0.08) 20/870injection containing a serotype 5 recombinant adeno-asso-
ciated virus vector carrying a normal human RPE65 cDNA
(Pang et al., 2006). Rod-mediated ERGs recorded from
treated eyes were robust and well formed in comparison to
untreated eyes, where ERGs were non-detectable except at
the highest stimulus intensities. The extent of functional
rescue depended on the timing of therapy consistent with
prior studies (Dejneka et al., 2004; Jacobson et al., 2005);
gene therapy performed early resulted in better retinal res-
cue. It is important to point out that we have previously
demonstrated that ERG functional measurements were
correlated with RPE65 expression levels, 11-cis retinalde-
hyde levels, rhodopsin levels, retinal histology, fundus
appearance, presence of all-trans retinal ester in the RPE,
and visually guided behavior in rd12 eyes seven months
after treatment at P14 (Pang et al., 2006). In addition, no
visual restoration was observed in any control eyes at any
time after treatment with AAV5-CBA-hGFP up to 18
months after treatment (Pang et al., 2005b).
Gene therapy also appeared to better rescue cone-med-
iated retinal function, but only when treatment occurred
early. This conclusion was inferred from comparisons in
the dark- and light-adapted temporal response functions.
First, for the P18 group, the light-adapted temporal
response function (Fig. 3B) overlapped the normal range
for the frequency range from 1 to 10 Hz (Fig. 3B). In con-
trast, the dark-adapted temporal-response function for
this group was only about half that of normal over this
same frequency range (Fig. 3A). Second, the biphasic
response function observed under dark-adapted condi-
tions for the earliest treatment group (Fig. 3A) is also con-
sistent with better preservation of cone structure and
function. The deXection of the temporal-response func-
tion into the normal range for the P18 group at the higher
temporal frequencies is due to cone intrusion above 10–
15 Hz. Rods cannot resolve temporal modulations above
10–15 Hz (Hecht & Shlair, 1935; Kelly, 1961), particularly
when the stimulus is relatively bright (1.66 cd-s/m2), as in
our experiments. The inXection at the higher temporal fre-
quencies is weakened at 6-months, and is absent at 13-
months, suggesting that the advantage exhibited by cones
at the earliest age of treatment is lost. The observation of
better cone rescue may, in part, explain prior Wndings of
better vision in daylight than under dim light conditions
after gene therapy in the RPE65 null mutation dog (Narf-
strom et al., 2003a).
The observation of detectable cone responses in the mice
for which treatment was delayed until 6- and 13-months
(Fig. 3B) was a surprise in light of two recent publications
showing a massive loss of cone photoreceptors over the Wrst
month of life in Rpe65¡/¡tm1Tmr homozygous mice (Chen,
Moiseyev, Takahashi, & Ma, 2006; Znoiko et al., 2005).
Nevertheless, cone photoreceptors were still clearly detect-
able by Xuorescent PNA staining at 4-weeks, the oldest age
tested (Chen et al., 2006) and it is conceivable that the
initial phase of massive loss is followed by a slower degen-
eration that would preserve cones for a longer period. This
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tors in the retinal degeneration slow (rds) mouse (Nir, Ked-
zierski, Chen, & Travis, 2000; Portera-Cailliau, Sung,
Nathans, & Adler, 1994). In addition, the Rpe65¡/¡ mouse
and the rd12 mouse models of LCA, may not be directly
comparable, as these mouse strains have diVerent underly-
ing mutations and diVerent funduscopic phenotypes (Pang
et al., 2005a), and the pattern of cone loss may not be the
same for these models. Alternatively, it is possible that the
light-adapted responses observed for the older age groups
in fact originate from desensitized rods (Seeliger et al.,
2001). Experiments are under way to determine the cellular
origin of the light-adapted responses for the older treat-
ment groups.
4.2. What are the characteristics of “vision” after retinal 
rescue in LCA animal models?
While gene replacement therapy has proven successful in
restoring retinal function in LCA animal models, less well
understood is the status of “vision” in these animals. In
humans and animals, limiting sensory input to the visual
system leads to severe and often irreversible visual deWcits
later in life (Birch & Stager, 1996; Ellemberg, Lewis,
Maurer, & Brent, 2000; Kawabata et al., 2003; Lewis et al.,
2002; Lewis et al., 1986; Lickey et al., 2004; McMullen,
Andrade, & Stahl, 2004; Prusky et al., 2000; Tian & Copen-
hagen, 2003). Several studies have included tests of visually
guided behavior that presumably reXect the performance of
the entire visual system in LCA animal models. In the Bri-
ard dog (Narfstrom et al., 2003a), behavioral tests have
included assessment of the ability to navigate a maze and to
follow a strong beam of light on the wall in a dimly lit
room. More recently, and more quantitatively, visual per-
formance in the Morris water maze under dark-adapted
conditions showed that rd12 mice treated in just one eye
perform similarly to normally sighted C57BL/6J mice,
while untreated rd12 mice perform very poorly (Pang et al.,
2006). Beyond these simple behavioral tasks, little is know
about the overall phenomenon of vision in these treated
animals. Our experiments were designed to address this
question.
4.3. Cortical visual function in treated rd12 mice
A comparison of ERG and VEP parameters provided a
mechanism for testing the integrity of the visual pathway
after gene replacement therapy. Since, ERG and VEP
responses possess a constant relation with each other in
normal animals, we argue that departures from this relation
in treated animals imply dysfunction in the post-retinal
visual pathway. This type of analysis is independent of the
overall status of retinal function.
Dark-adapted intensity-response functions recorded
from the visual cortex were in good agreement with the
expectations based on the amount of restored retina (see
Fig. 2B). We used the relative ERG Vmax amplitudes for thethree treatment groups to scale the normal VEP to provide,
as a Wrst approximation, the corresponding predicted VEP
response functions. The actual VEP data were in close cor-
respondence to predictions (Fig. 2B) except at the oldest
age of treatment where, in addition to amplitude reduc-
tions, a pronounced loss of sensitivity (k) was also
observed. Overall, the observations for the early treatment
ages would suggest a relatively intact visual pathway for the
channels carrying high contrast and low temporal fre-
quency luminance information.
The correspondence between actual and predicted
response functions is lost when luminance information is
modulated at higher temporal frequencies as shown in
Fig. 4A. Dark-adapted VEP temporal-response func-
tions were below predicted values at intermediate
temporal frequencies for the eyes treated at P18, and at
all but 1 Hz for the eyes treated at 6- and 13-months. The
systematic loss of high temporal frequency response
with age of treatment and the shift in waveform
morphology is consistent with loss of function for visual
pathways carrying high temporal frequency luminance
information.
A similar pattern of results was observed for the light-
adapted temporal response functions. Light-adapted
VEP temporal-response functions were below normal
values at all temporal frequencies and, as with the dark-
adapted temporal-response VEPs, the departures were
greatest for later treatment ages. In addition, there is a
systematic shift in waveform morphology with age of
treatment. The waveform for normal controls is bimodal,
with peaks at approximately 2 and 4 Hz, that is the result
of two independent channels having diVerent temporal
processing abilities reaching the cortex out of phase (Rid-
der, III & Nusinowitz, 2006). A modest suggestion of a
bimodal function is apparent in the response function for
the mice treated at P18 (Fig. 4B), but not at 6- and 13-
months. Overall, these results would suggest that visual
pathways carrying high temporal frequency luminance
information are disrupted even at the earliest age of
treatment.
Finally, we measured the VEP to stimuli that varied in
spatial frequency to estimate visual acuity. Signals that
were clearly distinguishable from background noise
were detectable for all treatment groups, although the
number of spatial frequencies where clear signal was
detectable decreased with age of treatment. These results
are consistent with prior light microscopy observations
(Pang et al., 2005a). In untreated rd12 eyes, the outer
nuclear layer (ONL) appears relatively normal until 3-
months of age, although there are obvious voids in the
photoreceptor outer-segments that become more pro-
nounced by 7-months of age, when 6–8 layers of cells
in the outer nuclear layer (ONL) remain in the mutant
retina, and the outer-segments are clearly shorter.
These voids in the photoreceptor layer would be expected
to progressively reduce spatial resolution and visual
acuity.
S. Nusinowitz et al. / Vision Research 46 (2006) 3926–3934 39335. Conclusion
Consistent with prior studies, early gene replacement
therapy resulted in better retinal rescue, and in particular,
better rescue of cone-mediated function. Cortical visual
function generally corresponded to the degree of retinal
rescue for luminance information modulated at low tempo-
ral frequencies, except at the oldest age of treatment, where
disruption of the visual pathway was suggested. However,
processing of high temporal and spatial information at the
visual cortex was compromised at all treatment ages, sug-
gesting there are multiple, partially overlapping sensitive
periods of development and that the sensitive period for
each speciWc visual function may be diVerent (Harwerth &
Levi, 1983). These results provide further support that early
treatment in human LCA will have the most hope for opti-
mal visual performance. However, it is diYcult to extrapo-
late these conclusions to anticipated gene replacement
therapy in aVected humans because systematic studies of
this sort have not yet been reported in LCA2 patients.
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